NO20052496L - Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter. - Google Patents
Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.Info
- Publication number
- NO20052496L NO20052496L NO20052496A NO20052496A NO20052496L NO 20052496 L NO20052496 L NO 20052496L NO 20052496 A NO20052496 A NO 20052496A NO 20052496 A NO20052496 A NO 20052496A NO 20052496 L NO20052496 L NO 20052496L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- drugs
- methods
- cgrp antagonists
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Foreliggende oppfinnelse angår CGRP-antagonister med den generelle formel (I) hvor A, U, V, W, X og R1 til R3 er definert som i krav 1, tautomerer, diastereomerer, enantiomerer, hydrater, blandinger derav og saltene derav så vel som hydrater av saltene, spesielt de fysiologisk akseptable salter derav med uorganiske eller organiske syrer, farmasøytiske preparater inneholdende disse forbindelser, anvendelse derav og fremgangsmåter for fremstilling av dem.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10250080A DE10250080A1 (de) | 2002-10-25 | 2002-10-25 | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
PCT/EP2003/011762 WO2004037810A1 (de) | 2002-10-25 | 2003-10-23 | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20052496D0 NO20052496D0 (no) | 2005-05-24 |
NO20052496L true NO20052496L (no) | 2005-06-24 |
Family
ID=32103086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20052496A NO20052496L (no) | 2002-10-25 | 2005-05-24 | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter. |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP1558600B1 (no) |
JP (1) | JP4401296B2 (no) |
KR (1) | KR20050074970A (no) |
CN (1) | CN1708493A (no) |
AR (1) | AR041718A1 (no) |
AT (1) | ATE394392T1 (no) |
AU (1) | AU2003276156A1 (no) |
BR (1) | BR0315665A (no) |
CA (1) | CA2503455A1 (no) |
CO (1) | CO5570704A2 (no) |
DE (2) | DE10250080A1 (no) |
DK (1) | DK1558600T3 (no) |
EA (1) | EA009219B1 (no) |
EC (1) | ECSP055747A (no) |
ES (1) | ES2306918T3 (no) |
HR (1) | HRP20050364A2 (no) |
IL (1) | IL168056A0 (no) |
MX (1) | MXPA05004375A (no) |
NO (1) | NO20052496L (no) |
PE (1) | PE20040592A1 (no) |
PL (1) | PL376450A1 (no) |
RS (1) | RS20050311A (no) |
TW (1) | TW200413317A (no) |
UA (1) | UA79323C2 (no) |
UY (1) | UY28034A1 (no) |
WO (1) | WO2004037810A1 (no) |
ZA (1) | ZA200502248B (no) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19963868A1 (de) * | 1999-12-30 | 2001-07-12 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
CN1293042C (zh) * | 2002-02-07 | 2007-01-03 | 远藤仁 | 芳香族氨基酸衍生物及其药物组合物 |
US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
US7595312B2 (en) | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
WO2005004869A1 (en) * | 2003-07-07 | 2005-01-20 | Boehringer Ingelheim International Gmbh | Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients |
TW200524601A (en) | 2003-12-05 | 2005-08-01 | Bristol Myers Squibb Co | Heterocyclic anti-migraine agents |
DE102004015723A1 (de) * | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
DE102004018795A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102004018796A1 (de) * | 2004-04-15 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7696195B2 (en) | 2004-04-22 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
ATE537153T1 (de) * | 2004-09-09 | 2011-12-15 | Merck Sharp & Dohme | Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors |
US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7384931B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
DE102004063752A1 (de) * | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen |
DE102004063753A1 (de) * | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
DE102004063755A1 (de) * | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
CN101146799A (zh) * | 2005-03-23 | 2008-03-19 | 贝林格尔·英格海姆国际有限公司 | Cgrp拮抗剂、其制备方法以及其作为药物的用途 |
EP1770091A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7491717B2 (en) | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
US7439237B2 (en) | 2005-04-15 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102005038831A1 (de) * | 2005-08-17 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
EP1770087A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
EP1770086A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102005050892A1 (de) | 2005-10-21 | 2007-04-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102006017827A1 (de) | 2006-04-13 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue kristalline Verbindungen |
PE20080153A1 (es) | 2006-06-08 | 2008-04-14 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp) |
DE102007038250A1 (de) * | 2007-08-13 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Herstellverfahren |
BRPI0817835A2 (pt) | 2007-10-18 | 2015-03-31 | Boehringer Ingelheim Int | Antagonistas cgrp |
EP2065381A1 (de) | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP Antagonisten |
EP2225223B1 (de) | 2007-11-22 | 2017-01-11 | Boehringer Ingelheim International GmbH | Organische verbindungen |
US8633228B2 (en) | 2008-08-01 | 2014-01-21 | Mitsui Chemicals Agro, Inc. | Amide derivative, pest control agent containing the amide derivative, and pest controlling method |
PT2396081T (pt) | 2009-02-16 | 2017-07-11 | Nogra Pharma Ltd | Compostos alquilamido e suas utilizações |
CA2864059C (en) | 2012-02-09 | 2020-04-28 | Nogra Pharma Limited | Methods of treating fibrosis |
EP3495363B1 (en) | 2016-07-28 | 2023-08-23 | Shionogi & Co., Ltd | Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect |
LT3668853T (lt) | 2017-08-16 | 2022-03-10 | Glaxosmithkline Intellectual Property Development Limited | Nauji junginiai |
CN111801330B (zh) | 2018-01-26 | 2024-04-05 | 盐野义制药株式会社 | 具有多巴胺d3受体拮抗作用的稠环化合物 |
EA202192207A1 (ru) | 2019-02-08 | 2021-10-27 | Ногра Фарма Лимитед | Способ получения 3-(4'-аминофенил)-2-метоксипропионовой кислоты и ее аналогов и промежуточных соединений |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2345357A1 (en) * | 1998-09-30 | 2000-04-06 | Merck Sharp & Dohme Limited | Benzimidazolinyl piperidines as cgrp ligands |
DE19937304C2 (de) * | 1999-08-10 | 2003-08-21 | Boehringer Ingelheim Pharma | Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen |
-
2002
- 2002-10-25 DE DE10250080A patent/DE10250080A1/de not_active Withdrawn
-
2003
- 2003-10-22 UY UY28034A patent/UY28034A1/es not_active Application Discontinuation
- 2003-10-23 PL PL03376450A patent/PL376450A1/xx not_active Application Discontinuation
- 2003-10-23 CA CA002503455A patent/CA2503455A1/en not_active Abandoned
- 2003-10-23 KR KR1020057007144A patent/KR20050074970A/ko not_active Application Discontinuation
- 2003-10-23 MX MXPA05004375A patent/MXPA05004375A/es not_active Application Discontinuation
- 2003-10-23 UA UAA200504872A patent/UA79323C2/uk unknown
- 2003-10-23 AT AT03809317T patent/ATE394392T1/de active
- 2003-10-23 CN CNA2003801020040A patent/CN1708493A/zh active Pending
- 2003-10-23 WO PCT/EP2003/011762 patent/WO2004037810A1/de active IP Right Grant
- 2003-10-23 AU AU2003276156A patent/AU2003276156A1/en not_active Abandoned
- 2003-10-23 BR BR0315665-6A patent/BR0315665A/pt not_active Expired - Fee Related
- 2003-10-23 JP JP2004545963A patent/JP4401296B2/ja not_active Expired - Fee Related
- 2003-10-23 DE DE50309807T patent/DE50309807D1/de not_active Expired - Lifetime
- 2003-10-23 ES ES03809317T patent/ES2306918T3/es not_active Expired - Lifetime
- 2003-10-23 DK DK03809317T patent/DK1558600T3/da active
- 2003-10-23 EP EP03809317A patent/EP1558600B1/de not_active Expired - Lifetime
- 2003-10-23 PE PE2003001077A patent/PE20040592A1/es not_active Application Discontinuation
- 2003-10-23 RS YUP-2005/0311A patent/RS20050311A/sr unknown
- 2003-10-23 EA EA200500600A patent/EA009219B1/ru not_active IP Right Cessation
- 2003-10-24 TW TW092129640A patent/TW200413317A/zh unknown
- 2003-10-24 AR ARP030103889A patent/AR041718A1/es unknown
-
2005
- 2005-03-17 ZA ZA200502248A patent/ZA200502248B/en unknown
- 2005-04-14 IL IL168056A patent/IL168056A0/en unknown
- 2005-04-22 HR HR20050364A patent/HRP20050364A2/hr not_active Application Discontinuation
- 2005-04-25 EC EC2005005747A patent/ECSP055747A/es unknown
- 2005-05-24 NO NO20052496A patent/NO20052496L/no not_active Application Discontinuation
- 2005-05-24 CO CO05050511A patent/CO5570704A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HRP20050364A2 (en) | 2006-05-31 |
AR041718A1 (es) | 2005-05-26 |
IL168056A0 (en) | 2009-02-11 |
EP1558600B1 (de) | 2008-05-07 |
WO2004037810A1 (de) | 2004-05-06 |
DK1558600T3 (da) | 2008-09-01 |
CO5570704A2 (es) | 2005-10-31 |
NO20052496D0 (no) | 2005-05-24 |
BR0315665A (pt) | 2005-08-30 |
EA200500600A1 (ru) | 2006-02-24 |
EA009219B1 (ru) | 2007-12-28 |
CA2503455A1 (en) | 2004-05-06 |
JP4401296B2 (ja) | 2010-01-20 |
EP1558600A1 (de) | 2005-08-03 |
ZA200502248B (en) | 2006-08-30 |
PL376450A1 (en) | 2005-12-27 |
PE20040592A1 (es) | 2004-10-27 |
CN1708493A (zh) | 2005-12-14 |
DE50309807D1 (de) | 2008-06-19 |
KR20050074970A (ko) | 2005-07-19 |
JP2006516244A (ja) | 2006-06-29 |
UY28034A1 (es) | 2004-05-31 |
MXPA05004375A (es) | 2005-07-05 |
ECSP055747A (es) | 2005-07-06 |
UA79323C2 (en) | 2007-06-11 |
RS20050311A (en) | 2007-08-03 |
TW200413317A (en) | 2004-08-01 |
AU2003276156A1 (en) | 2004-05-13 |
ES2306918T3 (es) | 2008-11-16 |
ATE394392T1 (de) | 2008-05-15 |
DE10250080A1 (de) | 2004-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20052496L (no) | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter. | |
NO20052493L (no) | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger. | |
NO20064166L (no) | Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter | |
TW200606151A (en) | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | |
NO20062713L (no) | 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister | |
TW200603799A (en) | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | |
NO20023161L (no) | Substituerte piperidiner, legemidler inneholdende disse forbindelser og fremgangsmåter for fremstilling av dem | |
NO20044826L (no) | Pyrrolidinderivater | |
NO20061839L (no) | Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav | |
WO2002098856A3 (en) | Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists | |
NO20060146L (no) | Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav | |
NO20060147L (no) | Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav | |
NO20060195L (no) | Kinolylamidderivater som CCR-5-antagonister | |
NO20070432L (no) | Pyrimidinureaderivater som kinaseinhibitorer | |
NO20071137L (no) | Nye piperidinderivater for behandling av depresjon | |
NO20054787D0 (no) | Indenderivater som farmasotiske midler | |
NO20052683L (no) | Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
ECSP045378A (es) | Derivados novedosos de diazabiciclononeno | |
NO20045486L (no) | Nye forbindelser og deres anvendelse | |
NO20062491L (no) | Benzoksazinderivter og deres anvendelse | |
NO20076680L (no) | Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter | |
NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
WO2004014869A3 (en) | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors | |
YU30902A (sh) | Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju | |
NO20040881L (no) | Orale antidiabetes midler. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |